Mylan purchases two dermatological products from Valeant
Mylan has purchased two dermatological products, Clindamycin Phosphate / Benzoyl Peroxide Gel and Fluorouracil 5% USP cream, from Valeant Pharmaceuticals.
Mylan has acquired the abbreviated new drug application (ANDA) of the generic version of Valeant's BenzaClin, Clindamycin Phosphate / Benzoyl Peroxide Gel.
Mylan also has purchased a license to manufacture and market Fluorouracil 5% USP cream as the exclusive authorized generic to Valeant's Efudex.
Clindamycin Phosphate / Benzoyl Peroxide Gel, 1%/5%, is indicated for the topical treatment of acne vulgaris.
Fluorouracil 5% USP cream, is recommended for the topical treatment of multiple actinic or solar keratoses and for the treatment of superficial basal cell carcinomas when conventional methods are impractical.
Mylan CEO Heather Bresch said the acquisition will allow them to expand their portfolio of difficult-to-manufacture or limited-competition products.
Related Insight
Suppliers Directory
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.
Production & Manufacturing > Manufacturing > Suppliers
Cryo Store – Biobanking, Packaging and Logistics of Temperature Sensitive Products
Cryo Store bv is based in the Netherlands and specialises in biobanking, packaging and logistics of temperature sensitive products and samples of various nature.
Production & Manufacturing > Manufacturing > Suppliers
Softbox - Temperature Control Packaging Systems
Softbox design and manufacture temperature control packaging and cold chain - shipping containers for the distribution of biotech, biomedical, clinical trial and finished pharmaceutical products.
Production & Manufacturing > Manufacturing > Suppliers
TBM Consulting Group - Lean Sigma Manufacturing Services
The global fallout from the real estate and banking crisis has impacted economies worldwide since 2009 and is likely to carry over well into 2012. The drop in consumer demand, capital spending cuts, layoffs, rising unemployment, the spectre of inflation and erratic equity markets has put intense pressure on margins and heightened everyone’s focus on cutting costs.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Curse of the Pharaohs? Analysis of Mycotoxins
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
Biocatalysis
Published by IRIS Biotech
Production & Manufacturing > Manufacturing > White Papers
Hygienic Processing Pharmaceutical
Published by Burkert Fluid Control Systems
Production & Manufacturing > Manufacturing > White Papers
Improved R&D Efficiency in Compound Synthesis, Confirmation and Purification
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.